Markus Riederer - Idorsia VP Biology

All Insiders . USA . 
Stock . Idorsia . Stakeholders . Insider . Markus Riederer
IDRSF Stock  USD 4.75  0.25  5.00%   

Insider

Markus Riederer is VP Biology of Idorsia
Age 61
Phone41 58 844 10 10
Webhttps://www.idorsia.com

Idorsia Management Efficiency

The company has return on total asset (ROA) of (0.4196) % which means that it has lost $0.4196 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (64.6068) %, meaning that it generated substantial loss on money invested by shareholders. Idorsia's management efficiency ratios could be used to measure how well Idorsia manages its routine affairs as well as how well it operates its assets and liabilities.
Idorsia has accumulated 1.13 B in total debt with debt to equity ratio (D/E) of 5.53, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Idorsia has a current ratio of 4.59, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Idorsia until it has trouble settling it off, either with new capital or with free cash flow. So, Idorsia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Idorsia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Idorsia to invest in growth at high rates of return. When we think about Idorsia's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Perry CelentanoValneva SE
N/A
Yuehui XieLifeTech Scientific
54
Chris EricksenWashTec AG
N/A
Douglas BakerPanamera Holdings
69
Dietrich StberBasilea Pharmaceutica AG
N/A
Marc MDBasilea Pharmaceutica AG
59
Jianxiong LiuLifeTech Scientific
52
Yuemei YanAscletis Pharma
53
Kristjan GudmundssonAscletis Pharma
55
Katarzyna BobrowArjo AB
43
Arjun KumarWashTec AG
N/A
Michael FrankelWashTec AG
N/A
Kornelia RasmussenArjo AB
46
Amir JavidanWashTec AG
N/A
Ruud OutersterpPharming Group NV
59
Jodi SampsonNanosonics Limited
N/A
Stephen ToorPharming Group NV
52
Hejingdao WuAscletis Pharma
49
Jeroen WakkermanPharming Group NV
54
Ursula EberhardtBasilea Pharmaceutica AG
61
Joshua DrummValneva SE
N/A
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland. Idorsia Ag is traded on OTC Exchange in the United States. Idorsia [IDRSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-64.61
Return On Asset-0.42

Idorsia Leadership Team

Elected by the shareholders, the Idorsia's board of directors comprises two types of representatives: Idorsia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Idorsia. The board's role is to monitor Idorsia's management team and ensure that shareholders' interests are well served. Idorsia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Idorsia's outside directors are responsible for providing unbiased perspectives on the board's policies.
Simon Jose, Executive Vice President Chief Commercial Officer, Member of the Executive Board
Andrew Weiss, Sr Communications
Olivier Lambert, Sr Assurance
Christoph Boss, VP Chemistry
Martine Clozel, Executive Vice President Chief Scientific Officer, Member of the Executive Board
Alexander Khatuntsev, VP HR
JeanPaul MD, CEO Director
Andr Muller, Ex CFO
Julien LLM, Group VP
Guy MD, Ex Officer
Markus Riederer, VP Biology

Idorsia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Idorsia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-64.61
Return On Asset-0.42
Operating Margin(8.25) %
Current Valuation3.08 B
Shares Outstanding187.56 M
Shares Owned By Insiders36.02 %
Shares Owned By Institutions23.03 %
Price To Book28.08 X
Price To Sales53.34 X
Revenue97.1 M

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies

Other Information on Investing in Idorsia Pink Sheet

Idorsia financial ratios help investors to determine whether Idorsia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Idorsia with respect to the benefits of owning Idorsia security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY